References
- 1. Hall IP. How will genetic approaches assist in the management of respiratory diseases? Curr Opin Pharmacol. 2009; 9:256-61.10.1016/j.coph.2009.03.003
- 2. Owen C, Stockley R. Molecular biology and respiratory disease. I- Basic principles. Thorax. 1990; 45:52-6.10.1136/thx.45.1.52
- 3. Cottin V. Clinical genetics for the pulmonologist: introduction. Respiration. 2007; 74:3-7.
- 4. Rowe S, Miller S, Sorscher E. Cystic fibrosis. N Engl J Med. 2005; 352:1992-2001.
- 5. Choe Y, Ko J, Seo J, Han J, Shim J, Koh Y, et al. Novel CFTR mutations in a Korean infant with cystic fibrosis and pancreatic insufficiency. J Korean Med Sci. 2010; 25:163-5.10.3346/jkms.2010.25.1.163
- 6. Collins F. Genetics terminology for respiratory physicians. Paediatr Respir Rev. 2009; 10:124-33.10.1016/j.prrv.2009.04.003
- 7. Fu J, Festen EA, Wijmenga C. Multi-ethnic studies in complex traits. Hum Mol Genet. 2011; 20:R206-13.10.1093/hmg/ddr386
- 8. Ober C, Hoffjan S. Asthma genetics 2006: the long and winding road to gene discovery. Genes Immun. 2006; 7:95-100.10.1038/sj.gene.6364284
- 9. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature. 2007; 448:470-3.
- 10. Leung TF, Sy HY, Ng MC, Chan IH, Wong GW, Tang NL, et al. Asthma and atopy are associated with chromosome 17q21 markers in Chinese children. Allergy. 2009; 64:621-8.
- 11. Tamari M, Tomita K, Hirota T. Genome-wide association studies of asthma. Allergol Int. 2011; 60: 247-52.10.2332/allergolint.11-RAI-0320
- 12. Himes BE, Hunninghake GM, Baurley JW, Rafaels NM, Sleiman P, Strachan DP, et al. Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet. 2009; 84:581-93.
- 13. Boezen HM. Genome-wide association studies: what do they teach us about asthma and chronic obstructive pulmonary disease? Proc Am Thorac Soc. 2009; 6: 701-3.10.1513/pats.200907-058DP
- 14. Kabesch M. Novel asthma-associated genes from genome-wide association studies: what is their significance? Chest. 2010; 137:909-15.10.1378/chest.09-1554
- 15. Mak JC. Pathogenesis of COPD. Part II. Oxidativeantioxidative imbalance. Int J Tuberc Lung Dis. 2008; 12:368-74.
- 16. Abboud RT, Vimalanathan S. Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema. Int J Tuberc Lung Dis. 2008; 12:361-7.
- 17. Roth M. Pathogenesis of COPD. Part III. Inflammation in COPD. Int J Tuberc Lung Dis. 2008; 12:375-80.
- 18. Teramoto S. 1. COPD pathogenesis from the viewpoint of risk factors. Intern Med. 2007; 46:77-9.
- 19. Postma DS, Boezen HM. Rationale for the Dutch hypothesis. Allergy and airway hyperresponsiveness as genetic factors and their interaction with environment in the development of asthma and COPD. Chest. 2004; 126:96S-104S; discussion 59S-61S.
- 20. Seifart C, Plagens A. Genetics of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2007; 2:541-50.
- 21. Wood AM, Stockley RA. Alpha one antitrypsin deficiency: from gene to treatment. Respiration. 2007; 74:481-92.10.1159/000105536
- 22. Janciauskiene SM, Bals R, Koczulla R, Vogelmeier C, Kohnlein T, Welte T. The discovery of alpha1- antitrypsin and its role in health and disease. Respir Med. 2011.
- 23. Putra AC, Tanimoto K, Arifin M, Antariksa B, Hiyama K. Genetic variations in detoxification enzymes and HIF-1α in Japanese patients with COPD. Clin Respir J. in press.
- 24. Ishii T, Matsuse T, Teramoto S, Matsui H, Miyao M, Hosoi T, et al. Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Thorax. 1999; 54:693-6.10.1136/thx.54.8.693
- 25. Sundberg K, Johansson AS, Stenberg G, Widersten M, Seidel A, Mannervik B, et al. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis. 1998; 19: 433-6.
- 26. Yoshikawa M, Hiyama K, Ishioka S, Maeda H, Maeda A, Yamakido M. Microsomal epoxide hydrolase genotypes and chronic obstructive pulmonary disease in Japanese. Int J Mol Med. 2000; 5:49-53.
- 27. Matera MG, Calzetta L, Cazzola M. TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm Pharmacol Ther. 2010; 23:121-8.10.1016/j.pupt.2009.10.007
- 28. Zhan P, Wang J, Wei SZ, Qian Q, Qiu LX, Yu LK, et al. TNF-308 gene polymorphism is associated with COPD risk among Asians: meta-analysis of data for 6,118 subjects. Mol Biol Rep. 2011; 38:219-27.
- 29. Zhang S, Wang C, Xi B, Li X. Association between the tumour necrosis factor-alpha -308G/A polymorphism and chronic obstructive pulmonary disease: An update. Respirology. 2010.
- 30. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59:574-80.10.1136/thx.2003.019588
- 31. Obeidat M, Wain LV, Shrine N, Kalsheker N, Soler Artigas M, Repapi E, et al.A comprehensive evaluation of potential lung function associated genes in the SpiroMeta general population sample. PLoS One. 2011; 6:e19382.10.1371/journal.pone.0019382
- 32. Artigas MS, Loth DW, Wain LV, Gharib SA, Obeidat M, Tang W, et al. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet. 2011; 43:1082-90.
- 33. Soler Artigas M, Wain LV, Repapi E, Obeidat M, Sayers I, Burton PR, et al. Effect of five genetic variants associated with lung function on the risk of chronic obstructive lung disease, and their joint effects on lung function. Am J Respir Crit Care Med. 2011; 184:786-95.
- 34. Pillai SG, Kong X, Edwards LD, Cho MH, Anderson WH, Coxson HO, et al. Loci identified by genomewide association studies influence different diseaserelated phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010; 182: 1498-505.10.1164/rccm.201002-0151OC
- 35. Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, Demeo DL, et al. A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet. 2011.
- 36. Wang Y, Yang H, Li L, Wang H, Zhang C, Yin G, et al. Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. Eur J Cancer. 2010; 46:758-64.10.1016/j.ejca.2009.12.010
- 37. Hu Z, Wei Q, Wang X, Shen H. DNA repair gene XPD polymorphism and lung cancer risk: a meta-analysis. Lung Cancer. 2004; 46:1-10.10.1016/j.lungcan.2004.03.016
- 38. Hsu NY, Wang HC, Wang CH, Chang CL, Chiu CF, Lee HZ, et al. Lung cancer susceptibility and genetic polymorphism of DNA repair gene XRCC4 in Taiwan. Cancer Biomark. 2009; 5:159-65.10.3233/CBM-2009-0617
- 39. Piao JM, Kim HN, Song HR, Kweon SS, Choi JS, Yun WJ, et al. p53 codon 72 polymorphism and the risk of lung cancer in a Korean population. Lung Cancer. 2011.
- 40. Lind H, Zienolddiny S, Ryberg D, Skaug V, Phillips DH, Haugen A. Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. Lung Cancer. 2005; 50:285-90.
- 41. Putra AC, Tanimoto K, Arifin M, Hiyama K. Hypoxia inducible factor-1alpha polymorphisms are associated with genetic aberrations in lung cancer. Respirology. 2011.
- 42. Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, et al. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis. 2003; 24:1779-83.
- 43. Arifin M, Tanimoto K, Putra AC, Hiyama E, Nishiyama M, Hiyama K. Carcinogenesis and cellular immortalization without persistent inactivation of p16/ Rb pathway in lung cancer. Int J Oncol. 2010; 36: 1217-27.
- 44. Young RP, Hopkins RJ, Whittington CF, Hay BA, Epton MJ, Gamble GD. Individual and cumulative effects of GWAS susceptibility loci in lung cancer: associations after sub-phenotyping for COPD. PLoS One. 2011; 6:e16476.10.1371/journal.pone.0016476
- 45. Bernhardt WM, Warnecke C, Willam C, Tanaka T, Wiesener MS, Eckardt KU. Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol. 2007; 435:221-45.
- 46. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med. 2002; 41:79-83.
- 47. Koukourakis MI, Papazoglou D, Giatromanolaki A, Panagopoulos I, Maltezos E, Harris AL, et al. C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1alpha gene define HIF-1alpha protein expression in non-small cell lung cancer. Lung Cancer. 2006; 53:257-62.
- 48. Kim HO, Jo YH, Lee J, Lee SS, Yoon KS. The C1772T genetic polymorphism in human HIF-1alpha gene associates with expression of HIF-1alpha protein in breast cancer. Oncol Rep. 2008; 20:1181-7.
- 49. Ollerenshaw M, Page T, Hammonds J, Demaine A. Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet Cytogenet. 2004; 153:122-6.10.1016/j.cancergencyto.2004.01.014
- 50. Kuwai T, Kitadai Y, Tanaka S, Kuroda T, Ochiumi T, Matsumura S, et al. Single nucleotide polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma. Oncol Rep. 2004; 12:1033-7.
- 51. Konac E, Onen HI, Metindir J, Alp E, Biri AA, Ekmekci A. An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers. Cancer Detect Prev. 2007; 31:102-9.10.1016/j.cdp.2007.01.001
- 52. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000; 161:646-64.
- 53. Lawson W, Loyd J. The genetic approach in pulmonary fibrosis: can it provide clues to this complex disease? Proc Am Thorac Soc. 2006; 3:345-9.10.1513/pats.200512-137TK
- 54. Garcia CK. Idiopathic pulmonary fibrosis: update on genetic discoveries. Proc Am Thorac Soc. 2011; 8: 158-62.10.1513/pats.201008-056MS
- 55. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009; 361:2353-65.
- 56. Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev. 2008; 88:557-79.10.1152/physrev.00026.2007
- 57. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A. 2008; 105:13051-6.10.1073/pnas.0804280105
- 58. Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med. 2008; 178:729-37.10.1164/rccm.200804-550OC
- 59. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007; 356:1317-26.10.1056/NEJMoa066157
- 60. Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One. 2010; 5:e10680.10.1371/journal.pone.0010680
- 61. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report. 2008.
- 62. World Health Organization. Policy Statement: Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Geneva, World Health Organization; 2008.
- 63. Palomino JC. Molecular detection, identification and drug resistance detection in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol. 2009; 56: 103-11.10.1111/j.1574-695X.2009.00555.x
- 64. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J. 2008; 32: 1165-74.10.1183/09031936.00061808
- 65. Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2005; 5:62.10.1186/1471-2334-5-62
- 66. Prayle A, Atkinson M, Smyth A. Pneumonia in the developed world. Paediatr Respir Rev. 2011; 12:60-9.10.1016/j.prrv.2010.09.012
- 67. Mitchell AM, Mitchell TJ. Streptococcus pneumoniae: virulence factors and variation. Clin Microbiol Infect. 2010; 16:411-8.10.1111/j.1469-0691.2010.03183.x
- 68. Preston JA, Dockrell DH. Virulence factors in pneumococcal respiratory pathogenesis. Future Microbiol. 2008; 3:205-21.10.2217/17460913.3.2.205
- 69. Mitchell TJ. Virulence factors and the pathogenesis of disease caused by Streptococcus pneumoniae. Res Microbiol. 2000; 151:413-9.
- 70. Ohlenschlaeger T, Garred P, Madsen HO, Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med. 2004; 351:260-7.
- 71. Rantala A, Lajunen T, Juvonen R, Bloigu A, Silvennoinen-Kassinen S, Peitso A, et al. Mannosebinding lectin concentrations, MBL2 polymorphisms, and susceptibility to respiratory tract infections in young men. J Infect Dis. 2008; 198:1247-53.
- 72. Garcia-Laorden MI, Sole-Violan J, Rodriguez de Castro F, Aspa J, Briones ML, Garcia-Saavedra A, et al. Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. J Allergy Clin Immunol. 2008; 122:368-74, 74 e1-2.10.1016/j.jaci.2008.05.037
- 73. Ruskamp JM, Hoekstra MO, Postma DS, Kerkhof M, Bottema RW, Koppelman GH, et al. Polymorphisms in the mannan-binding lectin gene are not associated with questionnaire-reported respiratory tract infections in children. J Infect Dis. 2008; 198:1707-13.
- 74. Keynan Y, Juno J, Meyers A, Ball TB, Kumar A, Rubinstein E, et al. Chemokine receptor 5 big up tri, open32 allele in patients with severe pandemic (H1N1) 2009. Emerg Infect Dis. 2010; 16:1621-2.
- 75. Dawson TC, Beck MA, Kuziel WA, Henderson F, Maeda N. Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol. 2000; 156:1951-9.10.1016/S0002-9440(10)65068-7
- 76. Qin G, Liu Y, Zheng J, Ng IH, Xiang Z, Lam KT, et al. Type 1 responses of human Vgamma9Vdelta2 T cells to influenza A viruses. J Virol. 2011; 85:10109-16.10.1128/JVI.05341-11
- 77. Hall IP. Pharmacogenetics, pharmacogenomics and airway disease. Respir Res. 2002;3:10.10.1186/rr159
- 78. Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet. 1999; 56:247-58.10.1034/j.1399-0004.1999.560401.x
- 79. Taylor DR, Kennedy MA. Genetic variation of the beta(2)-adrenoceptor: its functional and clinical importance in bronchial asthma. Am J Pharmacogenomics. 2001; 1:165-74.10.2165/00129785-200101030-00002
- 80. Andarini S, Kikuchi T, Nukiwa M, Pradono P, Suzuki T, Ohkouchi S, et al. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res. 2004; 64:3281-7.
- 81. Vachani A, Moon E, Wakeam E, Albelda SM. Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol. 2010; 42:385-93.10.1165/rcmb.2010-0026RT
- 82. Cantero-Recasens G, Fandos C, Rubio-Moscardo F, Valverde MA, Vicente R. The asthma-associated ORMDL3 gene product regulates endoplasmic reticulum-mediated calcium signaling and cellular stress. Hum Mol Genet. 2010; 19:111-21.10.1093/hmg/ddp471
- 83. Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature. 2002; 418:426-30.
- 84. Allen M, Heinzmann A, Noguchi E, Abecasis G, Broxholme J, Ponting CP, et al. Positional cloning of a novel gene influencing asthma from chromosome 2q14. Nat Genet. 2003; 35:258-63.
- 85. Laitinen T, Polvi A, Rydman P, Vendelin J, Pulkkinen V, Salmikangas P, et al. Characterization of a common susceptibility locus for asthma-related traits. Science. 2004; 304:300-4.10.1126/science.1090010
- 86. Zhang Y, Leaves NI, Anderson GG, Ponting CP, Broxholme J, Holt R, et al. Positional cloning of a quantitative trait locus on chromosome 13q14 that influences immunoglobulin E levels and asthma. Nat Genet. 2003; 34:181-6.10.1038/ng1166
- 87. Nicolae D, Cox NJ, Lester LA, Schneider D, Tan Z, Billstrand C, et al. Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21. Am J Hum Genet. 2005; 76:349-57.10.1086/427763
- 88. Putra AC, Tanimoto K, Arifin M, Antariksa B, Hiyama K. Genetic variations in detoxification enzymes and HIF-1alpha in Japanese patients with COPD. Clin Respir J. 2011. DOI: 10.1111/j.1752-699X.2011.00255.x10.1111/j.1752-699X.2011.00255.x
- 89. Smolonska J, Wijmenga C, Postma DS, Boezen HM. Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years’ research. Am J Respir Crit Care Med. 2009; 180: 618-31.10.1164/rccm.200905-0722OC
- 90. Sapey E, Wood AM, Ahmad A, Stockley RA. Tumor necrosis factor-{alpha} rs361525 polymorphism is associated with increased local production and downstream inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010; 182:192-9.10.1164/rccm.200912-1846OC
- 91. van Moorsel CH, van Oosterhout MF, Barlo NP, de Jong PA, van der Vis JJ, Ruven HJ, et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. Am J Respir Crit Care Med. 2010; 182:1419-25.
- 92. Pantelidis P, Fanning GC, Wells AU, Welsh KI, Du Bois RM. Analysis of tumor necrosis factor-alpha, lymphotoxin-alpha, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001; 163:1432-6.10.1164/ajrccm.163.6.2006064
- 93. Morrison CD, Papp AC, Hejmanowski AQ, Addis VM, Prior TW. Increased D allele frequency of the angiotensin-converting enzyme gene in pulmonary fibrosis. Hum Pathol. 2001; 32:521-8.10.1053/hupa.2001.24321
- 94. Grutters JC, du Bois RM. Genetics of fibrosing lung diseases. Eur Respir J. 2005; 25:915-27.10.1183/09031936.05.00133404
- 95. Shi X, Zhou S, Wang Z, Zhou Z. CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung Cancer. 2008; 59: 155-63.10.1016/j.lungcan.2007.08.004
- 96. Lee KM, Kang D, Clapper ML, Ingelman-Sundberg M, Ono-Kihara M, Kiyohara C, et al. CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations. Cancer Epidemiol Biomarkers Prev. 2008; 17:1120-6.10.1158/1055-9965.EPI-07-2786
- 97. Gresner P, Gromadzinska J, Wasowicz W. Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer. Lung Cancer. 2007; 57:1-25.10.1016/j.lungcan.2007.02.002
- 98. Li X, Hu Z, Qu X, Zhu J, Li L, Ring BZ, et al. Putative EPHX1 Enzyme Activity Is Related with Risk of Lung and Upper Aerodigestive Tract Cancers: A Comprehensive Meta-Analysis. PLoS One. 2011; 6:e14749.10.1371/journal.pone.0014749
- 99. Taioli E, Benhamou S, Bouchardy C, Cascorbi I, Cajas-Salazar N, Dally H, et al. Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis. Genet Med. 2007; 9:67-73.10.1097/GIM.0b013e31803068b1
- 100. Okazaki I, Sugita M, Matsuki H, Billah SM, Watanabe T. Additional candidates to conventional genes susceptible for lung cancer and changing trend in Japan. Oncol Rep. 2010; 23:1493-500.
- 101. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006; 15:979-87.10.1158/1055-9965.EPI-05-0899
- 102. Langevin SM, Ioannidis JP, Vineis P, Taioli E. Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines. Pharmacogenet Genomics. 2010; 20:586-97.10.1097/FPC.0b013e32833c3892
- 103.Wang Y, Yang H, Li L, Wang H. Glutathione Stransferase T1 gene deletion polymorphism and lung cancer risk in Chinese population: a meta-analysis. Cancer Epidemiol. 2010; 34:593-7.10.1016/j.canep.2010.05.008
- 104. Ye Z, Song H, Higgins JP, Pharoah P, Danesh J. Five glutathione s-transferase gene variants in 23,452 cases of lung cancer and 30,397 controls: meta-analysis of 130 studies. PLoS Med. 2006; 3:e91.
- 105. Miller DP, Asomaning K, Liu G, Wain JC, Lynch TJ, Neuberg D, et al. An association between glutathione S-transferase P1 gene polymorphism and younger age at onset of lung carcinoma. Cancer. 2006; 107: 1570-7.
- 106. Miller DP, De Vivo I, Neuberg D, Wain JC, Lynch TJ, Su L, et al. Association between self-reported environmental tobacco smoke exposure and lung cancer: modification by GSTP1 polymorphism. Int J Cancer. 2003; 104:758-63.10.1002/ijc.10989
- 107. Zhang J, Gu SY, Zhang P, Jia Z, Chang JH. ERCC2 Lys751Gln polymorphism is associated with lung cancer among Caucasians. Eur J Cancer. 2010; 46: 2479-84.10.1016/j.ejca.2010.05.008
- 108. Kiyohara C, Takayama K, Nakanishi Y. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer. 2006; 54:267-83.10.1016/j.lungcan.2006.08.009
- 109.Wang Y, Yang H, Li H, Li L, Wang H, Liu C, et al. Association between X-ray repair cross complementing group 1 codon 399 and 194 polymorphisms and lung cancer risk: a meta-analysis. Cancer Lett. 2009; 285:134-40.
- 110.Wei B, Zhou Y, Xu Z, Xi B, Cheng H, Ruan J, et al. The effect of hOGG1 Ser326Cys polymorphism on cancer risk: evidence from a meta-analysis. PLoS One. 2011; 6:e27545.
- 111. Yan L, Zhang D, Chen C, Mao Y, Xie Y, Li Y, et al. TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis. Int J Cancer. 2009; 125:2903-11.
- 112. Dai S, Mao C, Jiang L, Wang G, Cheng H. P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum Genet. 2009; 125:633-8.10.1007/s00439-009-0664-3
- 113. Hu Z, Li X, Qu X, He Y, Ring BZ, Song E, et al. Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis. 2010; 31:643-7.
- 114. Fong KM, Sekido Y, Gazdar AF, Minna JD. Lung cancer. 9: Molecular biology of lung cancer: clinical implications. Thorax. 2003; 58:892-900.10.1136/thorax.58.10.892
- 115. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008; 359:1367-80.
- 116. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007; 2:327-43.10.1097/01.JTO.0000263718.69320.4c
- 117. Minna JD, Fong K, Zochbauer-Muller S, Gazdar AF. Molecular pathogenesis of lung cancer and potential translational applications. Cancer J. 2002; 8 Suppl 1: S41-6.
- 118. Hiyama K, Hiyama E. Detection of telomerase activity in lung cancer tissues. Methods Mol Med. 2003; 74: 401-12.